Get started
Author

Ciara O’Brien

Observed names: Braun, Ciara O'Brien K Rammohan Mike, C. O'Brien, C. O’Brien, C.S. O'Brien, C.S. O’Brien, CS O'Brien, Ciara O'Brien, Ciara S O'Brien, Ciara S. O'Brien, Ciara S. O??Brien, Ciara S. O’Brien, Ciara S. O’brien, Ciara S. O’Brien, O'Brien, Ciara, O'Brien, Ciara S., O’Brien, Ciara
Observed institutions: Royal Cornwall Hospital Trust, Royal Cornwall Hospital, University of Manchester, Cancer Research UK Manchester Institute, The Christie Hospital, The Christie NHS Foundation Trust, Danish Cancer Society, Cardiff University, University of Wales
ORCID: 0000-0002-3769-1883
Observed ORCID: 0000-0002-3769-1883
OpenAlex ID: A5028638789
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
2019 · Dominic G. Rothwell, Mahmood Ayub, et al. · Nature Medicine · 290
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
2024 · Aditya Bardia, Komal Jhaveri, et al. · Journal of Clinical Oncology · 208
PDF
Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity
2015 · Bruno M. Simões, Ciara S. O’Brien, et al. · Cell Reports · 194
PDF
Antibiotic therapy: a major cause of drug-induced jaundice in southwest England
2007 · Syed H. Hussaini, Ciara S. O??Brien, et al. · European Journal of Gastroenterology & Hepatology · 88
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer
2023 · G. Viale, M. Basik, et al. · ESMO Open · 80
PDF
Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer
2022 · Chiara Francavilla, Ciara S. O'Brien · Open Biology · 73
Resistance to Endocrine Therapy: Are Breast Cancer Stem Cells the Culprits?
2009 · Ciara S. O’Brien, Sacha J. Howell, et al. · Journal of Mammary Gland Biology and Neoplasia · 63
Breast Cancer Stem Cells and Their Role in Resistance to Endocrine Therapy
2011 · Ciara S. O’Brien, Gillian Farnie, et al. · Hormones and Cancer · 61
PDF
A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity
2013 · Matthew P. Ablett, Ciara S. O’Brien, et al. · Oncotarget · 59
PDF
Prognostic Significance of CD44 and Orthopedia Homeobox Protein (OTP) Expression in Pulmonary Carcinoid Tumours
2016 · George Papaxoinis, Daisuke Nonaka, et al. · Endocrine Pathology · 58
Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis
2016 · Rachel Eyre, Denis G. Alférez, et al. · Journal of Mammary Gland Biology and Neoplasia · 49
PDF
Therapeutic mammaplasty is a safe and effective alternative to mastectomy with or without immediate breast reconstruction
2020 · S Potter, A Trickey, et al. · British journal of surgery · 41
PDF
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
2026 · Sara A. Hurvitz, Rachel M. Layman, et al. · Journal of Clinical Oncology · 21
Aortic Stenosis and Gastrointestinal Bleeding
2004 · Fyeza Hasan, Ciara S O'Brien, et al. · Journal of the Royal Society of Medicine · 21
PDF
Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics.
2022 · Giuseppe Viale, Naoki Niikura, et al. · Journal of Clinical Oncology · 20
The iBRA-2 (immediate breast reconstruction and adjuvant therapy audit) study: protocol for a prospective national multicentre cohort study to evaluate the impact of immediate breast reconstruction on the delivery of adjuvant therapy
2016 · Rajiv Dave, Rachel O'Connell, et al. · BMJ Open · 19
PDF
The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making
2021 · I. Whitehead, G. W. Irwin, et al. · BMC Cancer · 17
PDF
Abstract P3-07-28: SERENA-1: Updated analyses from a Phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer
2023 · Nicholas Turner, Christos Vaklavas, et al. · Cancer Research · 14
PDF
Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study
2022 · Hiba Fatayer, Rachel L O’Connell, et al. · British journal of surgery · 13
PDF
Are Stem-Like Cells Responsible for Resistance to Therapy in Breast Cancer?
2008 · Ciara S. O'Brien, Gillian Farnie, et al. · Breast Disease · 12
The NeST (neoadjuvant systemic therapy in breast cancer) study - Protocol for a prospective multi-centre cohort study to assess the current utilization and short-term outcomes of neoadjuvant systemic therapies in breast cancer
2019 · G. W. Irwin, F. Bannon, et al. · International Journal of Surgery Protocols · 7
PDF
TAS 102 in refractory metastatic colorectal cancer: UK Expanded Access Programme experience.
2017 · Ciara O'Brien, Sophia Callaghan, et al. · Journal of Clinical Oncology · 7
Abstract RF01-04: Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification
2024 · Senthil Damodaran, Fabrice André, et al. · Cancer Research · 5
Proteomics Identifies Osteomodulin as a Promoter of Breast Cancer Bone Metastasis via CDK1 Activation
2023 · Sara Cabral, Joseph Parsons, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 4
PDF
Novel Early Phase Clinical Trial Design in Oncology
2017 · Ciara O’Brien, Louise Carter, et al. · Pharmaceutical Medicine · 4
Works count: 58
Citation count: 1,444
H-index: 17
I10-index: 20
Year
Topic
Type